肝硬化门静脉高压诊治Baveno Ⅶ共识解读——介入科视角

周粟; 袁敏

doi:10.3969/j.issn.1671-038X.2023.02.04

肝硬化门静脉高压诊治Baveno Ⅶ共识解读——介入科视角

周粟¹,
袁敏^1, ,

- 上海市公共卫生临床中心介入科(上海，200093)
基金项目:
上海市卫生健康委员会卫生行业临床研究专项(No：202040333)

详细信息

通讯作者: 袁敏，E-mail：yuanmin@shaphc.org

中图分类号: R575.2

收稿日期: 2022-12-27

刊出日期: 2023-02-15

Consensus interpretation of Baveno Ⅶ in the diagnosis and treatment of portal hypertension in cirrhosis: perspective of interventional radiology department

ZHOU Su¹,
YUAN Min^1, ,

- Department of Interventional, Shanghai Public Health Clinical Center, Shanghai, 200093, China

More Information

Corresponding author: YUAN Min, E-mail: yuanmin@shaphc.org

Received Date: 27 December 2022

Publish Date: 15 February 2023

摘要

摘要: 2021年10月召开的Baveno Ⅶ专家共识会，总结了门静脉高压的主要进展及待解决的问题，介入诊疗是其重要内容，如：肝静脉压力梯度对门静脉高压的评估作用、危险分层指导治疗，经颈静脉肝内门体分流术在急性静脉曲张出血、静脉曲张出血二级预防、复发性腹水以及布加综合征、门静脉血栓等方面的应用。为了更好地规范和推动介入诊疗在门静脉高压诊治的临床及科研领域的应用，该文对其相关重点内容进行解读。
- Baveno Ⅶ共识 /
- 肝硬化门静脉高压 /
- 介入诊疗 /
- 解读
Abstract: The expert consensus meeting of Baveno Ⅶ held in October 2021 summarized the main progress and problems to be solved in portal hypertension, part of which involved interventional diagnosis and treatment. For example, hepatic vein pressure gradient(HVPG) has obvious advantages in the evaluation of portal hypertension, risk stratification guidance treatment and other fields. Transjugular intrahepatic portosystemic shunt(TIPS) plays an important role in acute varicose hemorrhage, secondary prevention of varicose hemorrhage, recurrent ascus, as well as the treatment of Budd-Chiari syndrome and portal thrombosis. In order to better standardize and promote the application of interventional diagnosis and treatment in the clinical and scientific research field of the diagnosis and treatment of portal hypertension, the relevant key contents were interpreted in this paper.
- Baveno Ⅶ consensus /
- cirrhotic portal hypertension /
- interventional diagnosis and treatment /
- interpretation

HTML全文

参考文献(22)

[1]	de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. doi: 10.1016/j.jhep.2021.12.022
[2]	Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005, 353(21): 2254-2261. doi: 10.1056/NEJMoa044456
[3]	Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology, 2007, 133(2): 481-488. doi: 10.1053/j.gastro.2007.05.024
[4]	Silva-Junior G, Turon F, Baiges A, et al. Timing affects measurement of portal pressure gradient after placement of transjugular intrahepatic portosystemic shunts in patients with portal hypertension[J]. Gastroenterology, 2017, 152(6): 1358-1365. doi: 10.1053/j.gastro.2017.01.011
[5]	Casado M, Bosch J, García-Pagán JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings[J]. Gastroenterology, 1998, 114(6): 1296-1303. doi: 10.1016/S0016-5085(98)70436-6
[6]	Rössle M, Siegerstetter V, Olschewski M, et al. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts[J]. Am J Gastroenterol, 2001, 96(12): 3379-3383. doi: 10.1016/S0002-9270(01)03902-8
[7]	D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review[J]. Hepatology, 1995, 22(1): 332-354.
[8]	Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding[J]. Hepatology, 2004, 40(4): 793-801. doi: 10.1002/hep.20386
[9]	García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding[J]. N Engl J Med, 2010, 362(25): 2370-2379. doi: 10.1056/NEJMoa0910102
[10]	Lv Y, Yang ZP, Liu L, et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(8): 587-598. doi: 10.1016/S2468-1253(19)30090-1
[11]	Nicoarǎ-Farcǎu O, Han GH, Rudler M, et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data[J]. Gastroenterology, 2021, 160(1): 193-205. e10. doi: 10.1053/j.gastro.2020.09.026
[12]	Sabri SS, Abi-Jaoudeh N, Swee W, et al. Short-term rebleeding rates for isolated gastric varices managed by transjugular intrahepatic portosystemic shunt versus balloon-occluded retrograde transvenous obliteration[J]. J Vasc Interv Radiol, 2014, 25(3): 355-361. doi: 10.1016/j.jvir.2013.12.001
[13]	Lee SJ, Kim SU, Kim MD, et al. Comparison of treatment outcomes between balloon-occluded retrograde transvenous obliteration and transjugular intrahepatic portosystemic shunt for gastric variceal bleeding hemostasis[J]. J Gastroenterol Hepatol, 2017, 32(8): 1487-1494. doi: 10.1111/jgh.13729
[14]	Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites[J]. Gastroenterology, 2017, 152(1): 157-163. doi: 10.1053/j.gastro.2016.09.016
[15]	Qi XS, Tian YL, Zhang W, et al. Covered TIPS for secondary prophylaxis of variceal bleeding in liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials[J]. Medicine(Baltimore), 2016, 95(50): e5680.
[16]	Mezawa S, Homma H, Ohta H, et al. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation[J]. Am J Gastroenterol, 2001, 96(4): 1155-1159. doi: 10.1111/j.1572-0241.2001.03694.x
[17]	Liu JC, Ma JQ, Yang CT, et al. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement[J]. Radiology, 2022, 303(3): 711-719. doi: 10.1148/radiol.211172
[18]	Han GH, Qi XS, Zhang W, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center[J]. Radiology, 2013, 266(2): 657-667. doi: 10.1148/radiol.12120856
[19]	Garcia-Pagán JC, Heydtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients[J]. Gastroenterology, 2008, 135(3): 808-815. doi: 10.1053/j.gastro.2008.05.051
[20]	Qi XS, Guo WG, He CY, et al. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre[J]. Liver Int, 2014, 34(8): 1164-1175. doi: 10.1111/liv.12355
[21]	Luo XF, Wang Z, Tsauo J, et al. Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding[J]. Radiology, 2015, 276(1): 286-293. doi: 10.1148/radiol.15141252
[22]	Lv Y, Qi XS, He CY, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial[J]. Gut, 2018, 67(12): 2156-2168. doi: 10.1136/gutjnl-2017-314634